Federal Circuit vacates “skinny label” ruling

The US Court of Appeals for the Federal Circuit has withdrawn a ruling that was criticised by some commentators for enhancing the risk of patent infringement liability for certain generic pharmaceutical companies.


Get unlimited access to all Global Competition Review content